GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Anika Therapeutics Inc (FRA:AKP) » Definitions » Cyclically Adjusted Revenue per Share

Anika Therapeutics (FRA:AKP) Cyclically Adjusted Revenue per Share : €9.26 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Anika Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Anika Therapeutics's adjusted revenue per share for the three months ended in Mar. 2024 was €2.536. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €9.26 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Anika Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 7.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 9.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Anika Therapeutics was 13.00% per year. The lowest was 7.40% per year. And the median was 9.95% per year.

As of today (2024-06-19), Anika Therapeutics's current stock price is €24.20. Anika Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €9.26. Anika Therapeutics's Cyclically Adjusted PS Ratio of today is 2.61.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Anika Therapeutics was 12.12. The lowest was 1.82. And the median was 6.63.


Anika Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Anika Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anika Therapeutics Cyclically Adjusted Revenue per Share Chart

Anika Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 5.47 7.30 8.35 8.83

Anika Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.29 8.79 9.30 8.83 9.26

Competitive Comparison of Anika Therapeutics's Cyclically Adjusted Revenue per Share

For the Medical Instruments & Supplies subindustry, Anika Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anika Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anika Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Anika Therapeutics's Cyclically Adjusted PS Ratio falls into.



Anika Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Anika Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.536/131.7762*131.7762
=2.536

Current CPI (Mar. 2024) = 131.7762.

Anika Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 1.248 100.560 1.635
201409 1.109 100.428 1.455
201412 1.272 99.070 1.692
201503 0.935 99.621 1.237
201506 1.331 100.684 1.742
201509 1.378 100.392 1.809
201512 1.848 99.792 2.440
201603 1.307 100.470 1.714
201606 1.566 101.688 2.029
201609 1.524 101.861 1.972
201612 1.818 101.863 2.352
201703 1.454 102.862 1.863
201706 1.980 103.349 2.525
201709 1.509 104.136 1.910
201712 1.647 104.011 2.087
201803 1.175 105.290 1.471
201806 1.753 106.317 2.173
201809 1.597 106.507 1.976
201812 1.657 105.998 2.060
201903 1.529 107.251 1.879
201906 1.911 108.070 2.330
201909 1.874 108.329 2.280
201912 1.823 108.420 2.216
202003 2.232 108.902 2.701
202006 1.919 108.767 2.325
202009 1.894 109.815 2.273
202012 1.881 109.897 2.255
202103 1.995 111.754 2.352
202106 2.164 114.631 2.488
202109 2.294 115.734 2.612
202112 2.146 117.630 2.404
202203 2.303 121.301 2.502
202206 2.578 125.017 2.717
202209 2.785 125.227 2.931
202212 2.559 125.222 2.693
202303 2.417 127.348 2.501
202306 2.784 128.729 2.850
202309 2.655 129.860 2.694
202312 2.690 129.419 2.739
202403 2.536 131.776 2.536

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Anika Therapeutics  (FRA:AKP) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Anika Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=24.20/9.26
=2.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Anika Therapeutics was 12.12. The lowest was 1.82. And the median was 6.63.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Anika Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Anika Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Anika Therapeutics (FRA:AKP) Business Description

Traded in Other Exchanges
Address
32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.